Pulmatrix, Inc. PULM
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Pulmatrix, Inc. (PULM) is a healthcare company listed in the US with a market value of about $5M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -63%.
About Pulmatrix
Pulmatrix is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $1M in 2015 to $8M in 2024, growth of about 23.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 6% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $8M | $7M | $6M | $5M | $13M | $8M | $153000 | $335000 | $835000 |
| Net income | -$5M | -$10M | -$14M | -$19M | -$20M | -$19M | -$21M | -$21M | -$18M | -$28M |
| Free cash flow | — | -$11M | -$17M | -$19M | -$20M | -$13M | $3M | -$17M | -$15M | -$14M |
| EPS (diluted) | $-1.41 | $-2.62 | $-3.87 | $-5460.00 | $-8630.00 | $-13430.00 | $-24599.99 | $-99599.97 | $-186399.94 | $-375998.98 |
| Net margin | — | -122.5% | -193.5% | -310.3% | -390.2% | -152.8% | -260.4% | -13439.9% | -5389.8% | -3334.5% |
| ROIC | -107.2% | -86.2% | -43.5% | -46.8% | -32.0% | -31.2% | -139.8% | -122.8% | -103.4% | -154.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Pulmatrix pay a dividend?
Not currently.
Is Pulmatrix a good stock to buy?
We do not give buy or sell advice. Pulmatrix scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.